Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105247 · ClinicalTrials.gov registry record · Phase 1
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT01105247: Completed Phase 1 study, sponsored by Pharmacyclics.
NCT01105247 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 133 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (122% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01105247, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Primary Outcome
Number of participants who had experienced at least one treatment emergent AEs.
Interventions
- DRUG PCI-32765
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT01105247 record still lists
NCT01105247 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (122% higher).
The record links to 0 conditions, and to 1 intervention - of which PCI-32765 is the first listed.
NCT01105247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01105247 about?
NCT01105247 is a clinical study titled "Safety of PCI-32765 in Chronic Lymphocytic Leukemia". The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
What is the current status of trial NCT01105247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2010-05. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01105247?
The interventions under investigation include: PCI-32765 (DRUG).
Who is sponsoring clinical trial NCT01105247?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01105247's enrollment target sits among peer trials
133 432nd of 2000 higher than 1,569 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia